Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

Open access
Rudicell, Rebecca S., Kwon, Young Do, Ko, Sung-Youl, Pegu, Amarendra, Louder, Mark K., Georgiev, Ivelin S., Wu, Xueling, Zhu, Jiang, Boyington, Jeffrey C., Chen, Xuejun, Shi, Wei, Yang, Zhi-yong, Doria-Rose, Nicole A., McKee, Krisha, O'Dell, Sijy, Schmidt, Stephen D., Chuang, Gwo-Yu, Druz, Aliaksandr, Soto, Cinque, Yang, Yongping, Zhang, Baoshan, Zhou, Tongqing, Todd, John-Paul, Lloyd, Krissey E., Eudailey, Joshua, Roberts, Kyle E., Donald, Bruce R., Bailer, Robert T., Ledgerwood, Julie, NISC Comparative Sequencing Program, Mullikin, James C., Shapiro, Lawrence, Koup, Richard A., Graham, Barney S., Nason, Martha C., Connors, Mark, Haynes, Barton F., Rao, Srinivas S., Roederer, Mario, Kwong, Peter D., Mascola, John R., Nabel, Gary J.·2014·Journal of Virology

Abstract

Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1 antibodies has been identified. These antibodies can protect against lentiviral infection in nonhuman primates (NHPs), suggesting that passive antibody transfer would prevent HIV-1 transmission in humans. To increase the protective efficacy of such monoclonal antibodies, we employed next-generation sequencing, computational bioinformatics, and structure-guided design to enhance the neutralization potency and breadth of VRC01, an antibody that targets the CD4 binding site of the HIV-1 envelope. One variant, VRC07-523, was 5- to 8-fold more potent than VRC01, neutralized 96% of viruses tested, and displayed minimal autoreactivity. To compare its protective efficacy to that of VRC01 in vivo , we performed a series of simian-human immunodeficiency virus (SHIV) challenge experiments in nonhuman primates and calculated the doses of VRC07-523 and VRC01 that provide 50% protection (EC 50 ). VRC07-523 prevented infection in NHPs at a 5-fold lower concentration than VRC01. These results suggest that increased neutralization potency in vitro correlates with improved protection against infection in vivo , documenting the improved functional efficacy of VRC07-523 and its potential clinical relevance for protecting against HIV-1 infection in humans. IMPORTANCE In the absence of an effective HIV-1 vaccine, alternative strategies are needed to block HIV-1 transmission. Direct administration of HIV-1-neutralizing antibodies may be able to prevent HIV-1 infections in humans. This approach could be especially useful in individuals at high risk for contracting HIV-1 and could be used together with antiretroviral drugs to prevent infection. To optimize the chance of success, such antibodies can be modified to improve their potency, breadth, and in vivo half-life. Here, knowledge of the structure of a potent neutralizing antibody, VRC01, that targets the CD4-binding site of the HIV-1 envelope protein was used to engineer a next-generation antibody with 5- to 8-fold increased potency in vitro . When administered to nonhuman primates, this antibody conferred protection at a 5-fold lower concentration than the original antibody. Our studies demonstrate an important correlation between in vitro assays used to evaluate the therapeutic potential of antibodies and their in vivo effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.02213-14

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 282

Metadata

Authors
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., Shi, W., Yang, Z.-Y., Doria-Rose, N. A., McKee, K., O'Dell, S., Schmidt, S. D., Chuang, G.-Y., Druz, A., Soto, C., Yang, Y., Zhang, B., Zhou, T., Todd, J.-P., Lloyd, K. E., Eudailey, J., Roberts, K. E., Donald, B. R., Bailer, R. T., Ledgerwood, J., Program, N. C. S., Mullikin, J. C., Shapiro, L., Koup, R. A., Graham, B. S., Nason, M. C., Connors, M., Haynes, B. F., Rao, S. S., Roederer, M., Kwong, P. D., Mascola, J. R., & Nabel, G. J.
Venue
Journal of Virology
Published
2014-11
Volume
88
Issue
21
Pages
12669-12682
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W2108422942
Cited by
282
References
9
FWCI
12.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. https://app.cochat.ai/papers/10.1128/jvi.02213-14
The paper
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., Shi, W., Yang, Z.-Y., Doria-Rose, N. A., McKee, K., O'Dell, S., Schmidt, S. D., Chuang, G.-Y., Druz, A., Soto, C., . . . Nabel, G. J. (2014). Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology. https://doi.org/10.1128/jvi.02213-14

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.